Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants

Pediatrics

Volumn 125, Issue 2, 2010, Pages

  Williams, Paige L ^a,b   Marino, Miguel ^b   Malee, Kathleen ^c   Brogly, Susan ^a   Hughes, Michael D ^a,b   Mofenson, Lynne M ^d  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antiretroviral treatment; Bayley scales; Low birth weight; Maternal health; Mental development; Motor development

Indexed keywords

ANTIRETROVIRUS AGENT; ILLICIT DRUG; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CAREGIVER; CHILD; CHILD DEVELOPMENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; EDUCATIONAL STATUS; ETHNICITY; FEMALE; GENDER; GEOGRAPHY; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MENTAL DEVELOPMENT; MENTAL FUNCTION; MOTHER; MOTOR PERFORMANCE; MULTICENTER STUDY; NERVE CELL DIFFERENTIATION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMOTOR DEVELOPMENT; RACE; RISK FACTOR; RURAL POPULATION; SCORING SYSTEM; UNITED STATES; URBAN POPULATION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; CHILD DEVELOPMENT; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LOGISTIC MODELS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 76049110308     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-1112     Document Type: Article

References (44)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-1180
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484-494
3. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Infect Dis. 2001;183(4):539 -545
4. Suksomboon N, Poolsup N, Ket-aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32(3):293-311
5. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. April 29, 2009; pp. 1-90. Available at http://aidsinfo.nih. gov/ContentFiles/PerinatalGL.pdf. Accessed November 23, 2009.
6. Ayers KM, Clive D, Tucker WE Jr, Haijian G, de Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity and carcinogenicity bioassays in mice and rates. Fundam Appl Toxicol. 1996;32(2):148-158
7. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89(21):1602-1608
8. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol. 2004;199(2):151-161
9. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281(2):151-157
10. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30(30):203-213
11. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(4):380 -387
12. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. AIDS. 1998;12(14):1805-1813
13. Hanson IC, Antonelli A, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(5):463- 467
14. Brogly S, Williams P, Seage GR, et al. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr. 2006;41(4): 535-536
15. The European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111(1). Available at: www.pediatrics.org/cgi/content/full/111/1/e52
16. Moye J, Rich KC, Kalish LA. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr. 1996;128(1):58-69
17. Pacheco SE, McIntosh K, Lu M, Mofenson LM, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the Women and Infants Transmission Study. J Infect Dis. 2006;194(8):1089 -1097
18. Le Chenadec J, Mayaux M-J, Giuhenneuc-Jouyaux C, Blanche S, Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003;17(14):2053-2061
19. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr. 2005;94(11):1571-1577
20. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers. AIDS. 2004;18(15):2009 -2017
21. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;25(3):261-268
22. Lindegren ML, Rhodes PH, Gordon L, et al. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci. 2000;918:222-235
23. Mofenson LM, Muderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr. 2002;30(2):200 -215
24. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci. 2000;918:212-221
25. Dominguez K, Bertoli J, Fowler M, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < 5 years of age. Ann N Y Acad Sci. 2000;918:236-246
26. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. 2000;343(11):759-766
27. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354(9184):1084-1089
28. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17(12):1769-1785
29. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21(8):929-938
30. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003;33(2):175-183
31. Chase C, Ware J, Hittelman J, Blasini I, et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics. 2000;106(2). Available at: www.pediatrics.org/cgi/content/full/106/2/e25
32. Lindsey JC, Malee KM, Brouwers P, Hughes MD, PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119(3). Available at: www.pediatrics.org/cgi/content/full/119/3/e681
33. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118(4). Available at: www.pediatrics.org/cgi/content/full/118/4/e1139
34. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522-1528
35. Gona P, van Dyke R, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296(3):292-300
36. Bayley N. Manual for the Bayley Scales of Infant Development. San Antonio, TX: Psychological Corporation; 1969
37. Bayley N. Manual for the Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993
38. Schuler ME, Nair P, Harrington D. Developmental outcome of drug-exposed children through 30 months: a comparison of Bayley and Bayley-II. Psychol Assess. 2003;15(3):435-438
39. Brogly S, Williams P, Seage GR III, et al. Antiretroviral treatment in pediatric HIV in the United States: from clinical trials to clinical practice. JAMA. 2005;293(18):2213-2220
40. Macmillan C, Magder LS, Brouwers P, et al. Head growth and neurodevelopment of infants born to HIV-1-infected drug-using women. Neurology. 2001;57(8):1402-1411
41. Rodriguez EM, Mendez H, Rich K, et al. Maternal drug use in perinatal HIV studies: the Women and Infants Transmission Study. Ann N Y Acad Sci. 1993;693:245-248
42. Mellins CA, Smith R, O'Driscoll P, et al. High rates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. Pediatrics. 2003;111(2):384-393
43. Mercier F, Boulassel MR, Yassine-Diab B, et al. Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Ralpha on central and effector memory CD4+ and CD8+ T cell subsets. Clin Exp Immunol. 2008;152(1):72-80
44. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med. 2007;356(17):1705- 1707